The deal priced at below last closing price of $18.92. Jefferies, TD Securities, Leerink, Stifel and Wedbush are acting as joint book running managers for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYRE:
- Spyre Therapeutics announces common stock offering, no amount given
- Spyre Therapeutics announces poster presentations at UEGW 2025
- Spyre Therapeutics initiated with a Buy at Deutsche Bank
- Promising Developments and Strategic Trials Drive Buy Rating for Spyre Therapeutics
- Spyre Therapeutics announces first patient dosed in Phase 3 SKYWAY trial